{
    "organizations": [],
    "uuid": "670d661a0d93ed09cba4a2f67a34459ebeec67bd",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-bavarian-nordic-initiates-clinical/brief-bavarian-nordic-initiates-clinical-trial-with-novel-cancer-immunotherapy-idUSASM000IA6",
    "ord_in_thread": 0,
    "title": "BRIEF-Bavarian Nordic Initiates Clinical Trial With Novel Cancer Immunotherapy",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 19 (Reuters) - BAVARIAN NORDIC A/S:\n* REG-BAVARIAN NORDIC ANNOUNCES INITIATION OF CLINICAL TRIAL WITH NOVEL CANCER IMMUNOTHERAPY TARGETING BRACHYURY IN CANCER METASTASIS\n* OPEN-LABEL PHASE 1 TRIAL WILL EVALUATE SAFETY AND TOLERABILITY OF MVA-BN(Â®) BRACHYURY VACCINE Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-19T14:05:00.000+02:00",
    "crawled": "2018-01-20T17:49:14.042+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "bavarian",
        "nordic",
        "nordic",
        "announces",
        "initiation",
        "clinical",
        "trial",
        "novel",
        "cancer",
        "immunotherapy",
        "targeting",
        "brachyury",
        "cancer",
        "metastasis",
        "phase",
        "trial",
        "evaluate",
        "safety",
        "tolerability",
        "brachyury",
        "vaccine",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}